ABSTRACT: Technology transfer is a key foundational component in product commercialization. It is more than just the transfer of documents; it relates to all aspects of the transfer of knowledge and experience to the commercial manufacturing unit to ensure consistent, safe, and high-quality product. This is the first in a series of articles from the BioPhorum Operations Group (BPOG) member companies discussing best practices and benchmarking of biopharmaceutical technology transfer. In this article, we provide the common terminology developed by BPOG to accommodate both transferring and receiving organizations. We also review the key elements of a robust technology transfer business process, including critical milestones. Finally, we provide a brief overview of the articles in this series.
Introduction
Technology transfer (TT)-the transfer of product and process knowledge between development and manufacturing, and within or between manufacturing sites, to achieve product realization (ICH Q10)-is a critical business process in the biopharmaceutical industry. As processes are scaled up for commercial manufacturing or expanded to alternative sites for expansion or business risk mitigation, the effectiveness of TT can have a substantial effect on the realization of business goals. Given the highly technical nature of biopharmaceuticals and the professionals working in it, it is no surprise that we are quite good at TT from a technical perspective. However, companies feel that we could do it faster and more cost effectively to increase returns on expensive biopharmaceutical development and approval activities.
Understanding how to streamline and improve TTs is complicated by companies using different terminology and ways of working. This in turn makes assessments and meaningful metrics difficult to define. When, for example, does a TT begin-when a steering committee is formed, a project charter is approved, or when the receiving site is selected? Similarly the definition of the end of a TT was diverse between organizations, with variation between milestones such as the end of the campaign, lot disposition, regulatory submission, or regulatory dossier approval. It rapidly became clear to us that a common terminology and language was need for the sharing of current and future best practices. The sharing of the terminology, best practices, and of benchmarking within the BioPhorum Operations Group (BPOG) Technology Transfer Working Group is the goal of this series of articles. Figure 1 illustrates the key quality, technical, and business drivers that need to be balanced to ensure the success of TTs. TT is considered successful when we get it "right first time" with successful lot release and a minimal number of non-conformances or out-ofspecification events. From a technical perspective, it is necessary to demonstrate that the process scale-up and transfer is effective by analyzing key and critical process performance parameters and achieving targets *Corresponding Author: David Bain, Facilitator, BioPhorum Operations Group (BPOG) 5 Westbrook Court, Sharrow Vale Road Sheffield, S11 8YZ, United Kingdom. e-mail: david@biophorum.com doi: 10.5731/pdajpst.2015.01086
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for product quality attributes and process yield. The quality and technical drivers need to be achieved against the backdrop of business constraints. These include schedule and on-time delivery of product for clinical trials and product launch, and financial and resource considerations.
Definition of Terms
As noted in the introduction, it is important to ensure a common framework and terminology for a meaningful discussion. The TT framework discussed here refers to the transfer of biopharmaceutical processes from the sending unit to the receiving unit, the latter typically being a commercial manufacturing operation. This involves both process transfer and analytical transfer (method qualification, transfer, robustness, and validation or verification). The BPOG Technology Transfer Working Group definitions are summarized in Table I .
Key Activities and Milestones In Technology Transfer (TT) Activities
Once a set of terms were defined, we were able to discuss and compare the actual business process flow for TT. Although not identical, the prerequisites, responsible units, and the type of output for a given step in successful TTs were found to be highly similar. The activity flow for TTs (Table II) , based on the elements of successful transfers, was developed. This flow was similar between large companies and small companies, sending units (SUs) and receiving units (RUs), and between product sponsors/clients and Contract Manufacturing Organizations (CMOs). It is the basis of the TT business process outlined with a focus on late stage-Phase 3 clinical and process performance qualification (PPQ)-and post-licensure TTs. Many of the elements also apply to early-stage transfers. In addition, we identified key milestones for the TT, and these are summarized in Table II .
Articles In the Series
This is the first of a series of articles to reflect the current and best practices, as well as learnings from participants in the forum. With an industry-wide perspective, improvements can be made in the TT process that we trust will benefit the industry as a whole. Some of the topics addressed in later articles will include shakedown and engineering runs, and risk management in TT.
Conclusion
Using common terminology and language, current and future best practices can be shared across the industry. This article has outlined the necessary elements of business process flow for TTs that are highly similar throughout the biopharmaceutical industry. The comparisons and development of industry-wide best practices will provide greater efficiencies from improved ways of working. Once in place, Full-scale lots manufactured to supply material for its intended (therapeutic) use. These may include the process performance qualification (PPQ) and continuous process verification (CPV) lots and are targeted as product for commercial sale/distribution.
Comparability Studies
The demonstration that the quality attributes are highly similar and that the existing knowledge is sufficiently predictive to ensure that any differences in quality attributes have no adverse impact upon safety or efficacy of the drug product (ICH Q5E). Dry Runs Batch record (BR) walk down on the manufacturing shop floor to ensure that the BR record documentation aligns with manufacturing's ability to execute the process (transfer lines, sampling, sequence of operations, clarity of instructions). Synonym: batch record (BR) walk down.
Facility Fit
Determination of how the process will be executed at the receiving unit (RU) compared to the sending unit (SU). Captures all differences and/or gaps for end-to-end process execution. This includes facilities and equipment, cleaning and sterilization procedures, environmental health and safety procedures, raw materials and components handling, quality control (QC) and analytical activities, and quality systems.
Engineering Lots
Full-scale lots of the final process to demonstrate process performance and quality attributes at the receiving unit (RU) prior to process performance qualification (PPQ). These may be GMPs for the manufacture of clinical or commercial material. For clinical manufacturing, the engineering lots may be the clinical manufacturing lots. Synonyms: first full-scale clinical (FSC) lot, first clinical/commercial-scale lot (FCS).
Gap Analysis
Identification of risks for the process at the receiving unit (RU). Captures all differences and/or gaps in knowledge at the RU for end-to-end process execution. This includes facilities and equipment, cleaning and sterilization procedures, environmental health and safety procedures, raw materials and components handling, quality control (QC) and analytical activities, and quality systems. Synonyms: quality risk assessments (QRAs). Good Manufacturing Practice (GMP) Campaign
Full-scale lots manufactured to supply material for its intended (therapeutic) use. These can be clinical batches, process performance qualification (PPQ) batches, or commercial supply batches.
Feasibility Evaluation
Identification of major elements of a process which are different at the receiving unit (RU) compared to the sending unit (SU), that could affect transfer timing or feasibility including facilities and equipment, key procedures, raw materials and components handling, quality control (QC) and analytical support, and quality systems. Synonyms: technical evaluation, high-level gap analysis. High-Level Process Documentation Package
Generalized documents describing the process for the sending unit (SU) and receiving unit (RU). They do not include all details, but only sufficient information, for the high-level gap analysis and high-level TT plan.
High-Level Technology
Transfer Plan A site-specific but general plan for TT activities to assess major activities, investments, and feasibility. Synonym: high-level project plan. Laboratory Demonstration Demonstration runs, performed by the receiving unit (RU) and based on a predefined plan and acceptance criteria, showing the performance of the process or analytical methods at laboratory scale. This occurs prior to scale-up or method qualification. Synonym: method familiarization (typically performed by the RU). Process Documentation Package Documents describing the process for the sending unit (SU) and receiving unit (RU). May contain standard operating procedures (SOPs), master batch records (MBRs), process descriptions (PDs), development reports, validation reports, engineering drawings, material lists, sampling plan, etc. Synonym: technical documentation package (TDP). Ability of a process to tolerate variability of materials and changes of the process and equipment without negative impact on quality or productivity.
Process Transfer
The transfer of process and analytical knowledge between development and manufacturing, or between manufacturing sites, to establish the process at the receiving unit (RU). Process transfer is a subset of the activities for TT.
Process Transfer Completion
As defined in a study plan, successful disposition (release) of material from initial batch(es) by the receiving unit (RU).
Process Transfer Initiation
The providing of process and analytical knowledge by the sending unit (SU), usually in the form of the process documentation package, and commencement of activity at the receiving unit (RU) for detailed gap analysis and laboratory demonstration. Process Transfer Success Criteria
Pre-defined criteria for assessing the success or effectiveness of the process. These could be considered the key performance indicators (KPIs) of the process. Examples could be meeting drug substance (DS) specification and in process control action limits, comparability criteria, meeting drug substance/drug product (DS/DP) release dates, or no major rework or reprocessing required. Project Charter Document describing of the goals of the TT, including scope of process to be transferred, definition of the transferring and receiving sites, project team members and structure, governance structure, major milestones/deliverables, assumptions, risks, business benefits, and overall acceptable outcome.
Project Team
A team, having members with clearly defined key responsibilities, drawn from members of relevant disciplines from both the sending unit (SU) and receiving unit (RU) sites, to manage the TT. Synonym: core project team. Receiving Unit (RU)
The involved disciplines at an organization to where a designated product, process, or method is expected to be transferred. Sending Unit (SU)
The involved disciplines at an organization from where a designated product, process, or method is expected to be transferred.
Shakedown Lots
Experimental batches for execution of the process at scale for development of the final manufacturing process, automation, and operation. Shakedown runs are experimental only, and are not used for clinical or commercial supply manufacturing. The shake-down run includes use of cell culture or product containing feed streams. Synonym: not for human use (NfHU) run.
Stability Studies
Testing to provide evidence on how the quality of a drug substance, drug product, or placebo varies with time under the influence of a variety of environmental factors, such as temperature, humidity, and light, and to establish a retest period for the drug substance or a shelf life for the drug product and recommended storage conditions. Steering Committee
Team responsible for oversight/direction of the TT project/core team. The TT steering committee is typically composed of senior management members from the sending unit (SU) and receiving unit (RU) as well as additional functions as needed for critical oversight of the TT. Synonyms: TT oversight committee. Sub-Team A team, having members with clearly defined key responsibilities, with members representing the discipline from both the sending unit (SU) and receiving unit (RU), to oversee that disciplines activities as part of the TT. Examples include analytical, process, upstream, downstream, raw materials, production, regulatory affairs, quality control (QC), engineering, supply chain, etc. Synonym: workstream. Technology Transfer (TT)
The transfer of product and process knowledge between development and manufacturing, and within or between manufacturing sites to achieve product realization (ICH Q10).
Technology Transfer Completion
License/facility approval for manufacturing by the receiving unit (RU) of the transferred process, and demonstration of robust manufacturing.
Technology Transfer Initiation
Formal selection of the receiving unit (RU).
Technology Transfer Plan A document, approved by the sending unit (SU) and receiving unit (RU), defining the task assignments and responsibilities, acceptance criteria for gates and the completion of TT, documentation to be generated, and timing of activities. Synonym: technology transfer master plan (TTMP).
Technology Transfer Success Criteria
Pre-defined evaluation criteria for assessing the success or effectiveness of the TT process. These would include success of the process transfer, demonstration of robustness of the operation at the receiving unit, and license/facility approval for manufacturing.
these can result in reductions in timelines, costs, and regulatory risks. their contributions to this article. BPOG is a crossindustry collaboration that aims to share and develop operational best practices in the areas of drugs substance manufacturing, process development, and fill finish. Established in 2008, the BPOG community currently comprises more than 1200 active participants from 25 companies. More information can be found at www.biophorum.com. 
